Is Eli Lilly Stock Running out of Steam?

Eli Lilly has surged over 300% in five years driven by blockbuster GLP-1 drugs Mounjaro and Zepbound, which generated 56% revenue growth in Q1. While the stock trades at a premium 40x earnings valuation, analysts argue it remains justified given upcoming pipeline catalysts like retatrutide (projected $3.8B revenue by 2030) and potential new indications for GLP-1 drugs. The stock is down 11% from highs, presenting a potential entry point for long-term investors.